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Abstract 
Spray drying can be used to extend the shelf life of biologics stored at 
ambient temperature. Empirical and statistical design of experiments 
approaches typically require a relatively large number of experiments to 
determine suitable formulation and spray drying process parameters. An 
alternative approach, which may require fewer experiments, is to use 
mechanistic models to select these parameters. In this paper, mechanistic 
models are applied to develop a bacteriophage powder expected to have 
long-term physical stability at ambient temperature. The developed powder 
may be useful for decreasing incidences of foodborne illness in Kenya. 
Keywords: bacteriophage powder; glass transition temperature; 
supplemented phase diagram; spray drying; stability. 
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Empirical and statistical design of experiments approaches are commonly used for selecting 
formulation and process parameters during the development of spray dried biologic 
products. An alternative approach is to use mechanistic models developed based on an 
understanding of fundamental underlying principles. That is the approach undertaken in this 
work wherein a dry powder bacteriophage (phage) dosage form is designed to have target 
characteristics without requiring a substantial number of spray drying experiments. The 
powder is intended for use in broiler chicken feed to decrease Campylobacter jejuni in the 
chicken gut, with the end goal of decreasing the prevalence of foodborne illness in Kenya, 
which is abnormally high.[1,2] The development process can be divided into the following 
steps, discussed individually in this paper: 1) formulation; 2) atomization; 3) solvent 
evaporation and particle formation; 4) particle collection and analysis; 5) storage and 
transport.  
2. Materials and Methods 
A modified Büchi B-191 laboratory-scale spray dryer (Büchi Labortechnik AG; Flawil, 
Switzerland), schematically shown in Figure 1, was used to spray dry different myoviridae 
phages that can infect Campylobacter jejuni: CP30A, CP20, and CP8. These phages were 
isolated from chicken excreta and are present in chicken gut.[3] A transmission electron 
micrograph (TEM) of phage CP20 is given in Figure 2.  
 
Fig. 1 Schematic of the modified laboratory-scale Büchi B-191 spray dryer. 
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Fig. 2 TEM of phage CP20. 
2.1 Formulation 
The formulations were chosen to consist of L-leucine (Fisher Scientific, Cat. No. 
AC125121000; NH, USA) and D-(+)-trehalose dihydrate (Fisher BioReagents, Cat. No. 
BP2687; NH, USA) as dissolved solids in aqueous solution with phage (pH ~6.5). 
Trehalose is thought to stabilize biologics on drying by forming an amorphous glass that 
allows hydrogen bonds lost on desiccation of the biologic to be replaced.[4] Leucine forms a 
shell that decreases particle cohesiveness.[5]  
For spray drying experiments, stock phage lysates were filtered and centrifuged to reduce 
the impurity content to < 0.5 mg mL-1, and then diluted 1:100 into two aqueous 
formulations: (F1) 7.5 mg mL-1 leucine, 22.5 mg mL-1 trehalose; (F2) 12 mg mL-1 leucine, 
18 mg mL-1 trehalose. In the literature similar formulations have been successfully used to 
stabilize spray dried phage.[6-9] Further details regarding the choice of these formulations are 
given in the following sections. Plaque assay was used to measure the presence and extent 
of titer reduction due to dilution of phage into the above formulations. The results are 
presented in Section 3.1. 
2.2 Atomization 
The spray dryer uses a twin-fluid atomizer to generate droplets. An atomizing gas flow rate 
of 1.5×10-4 kg s-1 and a spray rate of 1.7×10-5 kg s-1 were used. A characteristic shear rate 
on the order of 1×105 s-1 was expected according to a model presented by Ghandi et al.[10] 
In the literature,[7] phage have remained active after atomization at similar shear rates. To 
verify minimal titer reduction, filtered phage CP30A lysate in formulation F1 was atomized 
onto a filter, from which liquid was drawn for assay. The results are presented in Section 
3.2. 
The air-to-liquid ratio (ALR), defined as the ratio of the mass flow rates of atomizing gas 
and liquid feed, was 8.8. From the ALR and data for the present atomizer given by Hoe et 
al.,[11] an initial droplet diameter of ~9 µm was predicted. Using a model presented by 
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Boraey et al.,[12] and the formulation compositions given in Section 2.1, the aerodynamic 
diameter at the time of shell formation was predicted to be ~2 µm, which can be collected 
with the cyclone.  
2.3 Solvent Evaporation and Particle Formation 
Solvent from the liquid droplets generated by atomization quickly evaporates into the 
drying chamber of the spray dryer. The surface temperature of the droplets is typically 
assumed to remain near the wet bulb temperature for most of the evaporation process due to 
evaporative cooling;[13] therefore, thermal deactivation of the phage is not expected during 
initial stages of solvent evaporation. The dissolved solid that reaches critical 
supersaturation at the surface first may nucleate and form a crystalline shell. This is the 
particle formation stage, which has been described by Vehring et al.[14] The formulation 
compositions in Section 2.1 were designed using mechanistic models such that leucine 
would reach supersaturation much earlier than trehalose, allowing for enough time to 
nucleate and crystallize leucine at the surface (11.5 milliseconds for F1 and 15.8 
milliseconds for F2). Since previous work has demonstrated that conditions similar to F1 
may not be sufficient for obtaining a fully crystalline leucine structure when phage lysate is 
present in the formulation, F2 was also tested with the expectation that it would form a fully 
crystalline leucine structure.[9]  
A spray dryer process model, developed based on similar models in the literature,[15,16] was 
used to predict the outlet temperature and the outlet relative humidity. The outlet 
temperature was predicted to be ~50°C and the outlet relative humidity ~3% for an inlet 
temperature of 70°C, a spray rate of 1.7×10-5 kg s-1, and a drying gas flow rate of 8.5×10-3 
kg s-1.  
2.4 Particle Collection and Analysis 
A cyclone was used to collect the powder in a glass collection bottle. The collection 
efficiency is defined as the percent of the mass of dissolved solids in the feed solution 
recovered in the collection bottle. The collected powder containing phage was analyzed for 
solid state using Raman spectroscopy (using a custom device developed by Wang et al.[17]) 
and for particle morphology using scanning electron microscopy (SEM) (Zeiss Sigma 
FESEM, Oberkochen, Germany). Results are presented in Section 3.4.  
2.5 Storage and Transport 
Moisture uptake during storage and transport can result in crystallization of trehalose, 
which is known to deactivate phage.[18] Therefore, it is crucial that the packaging material is 
moisture-equilibrated. In this study, a Steady State / Stability Test Chamber (910W-4, 
Lunaire Environmental, Williamsport, PA, USA) was used to equilibrate the powder and 
packaging to 4% relative humidity, with subsequent packaging occurring in the chamber. 
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The relative humidity was chosen according to moisture uptake data and the information 
contained in Figure 3, described below. The packaging consisted of the powder in a vial, 
which was packaged in a double heat-sealed aluminum foil bag along with a satchel of 
silica gel desiccant (McMaster Carr, 2189K16; Elmhurst, USA), all of which were further 
packaged in another double heat-sealed aluminum foil bag along with another satchel of 
silica gel desiccant. The packaged spray dried powder, along with liquid controls, were 
shipped from Edmonton, Canada, to Nottingham, UK, in a Styrofoam box to minimize 
temperature variations. The titer after the complete development and shipping process will 
be determined by resuspension of the powder and plaque assay. 
Throughout long-term stability studies, the powder should remain at a near-constant 
moisture content as, over time, moisture can lead to glass transition and crystallization. This 
tendency is demonstrated in a supplemented phase diagram that was developed for a 
trehalose-water system and is shown in Figure 3. With this diagram, the physical stability 
of the amorphous solid phase can be predicted a priori for a designed storage temperature, 
moisture content, and hence relative humidity. Use of this diagram is crucial for achieving 
long-term physical stability. The curve of the well-mixed glass transition temperature was 
developed using the Gordon-Taylor equation with a k-value of 5.9 and respective glass 
transition temperatures of 387 K for dry trehalose and 138 K for water.[19] As a rule of 
thumb, long-term storage should be performed for conditions at least 50°C below the glass 
transition temperature.[20] 
 
Fig. 3 Supplemented phase diagram developed for a trehalose-water system. Modified from Hoe et 
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3. Results and Discussion 
3.1 Formulation 
Filtered phage CP30A lysate had no titer reduction over a period of 20 days when stored at 
30°C in water, buffer, or formulation F1. A storage temperature of 40°C led to no titer 
reduction in buffer after 1 day but to > 1 log(pfu/mL) titer reduction after 10 days. A 
storage temperature of 50°C led to no titer reduction in buffer for at least 6 hours. No titer 
reduction was observed shipping CP30A in F1 within a vial in a Styrofoam box without 
temperature control from Nottingham, UK, to Edmonton, Canada, and back. This stability 
indicated that it is feasible to perform liquid control measurements with each experiment.  
3.2 Atomization 
The atomization titer reduction of phage CP30A in F1 was ~0.25 log(pfu/mL), which is less 
than the value of ~0.75 log(pfu/mL) reported in the literature for phages PEV2 and 
PEV40,[7] where similar predicted shear rates were used. 
3.3 Solvent Evaporation and Particle Formation 
The outlet temperature matched predictions from the process model within 2°C.  
3.4 Particle Collection and Analysis 
The collection efficiency was 54% for both formulations, which is typical for nominal 
batch sizes of ~1.5 grams. Raman spectroscopy confirmed trehalose was amorphous while 
leucine was mostly crystalline for both formulations. SEM (Figure 4) indicated that the 
phage lysate affected the particle morphology. It is possible that residual components in the 
phage lysate concentrated on the surface and interfered with the sensitive shell deformation 
and crystallization processes. This morphology was also present for other phage spray dried 
with leucine and trehalose in the literature, for which good powder flowability and long-
term biological stability at 20°C were still achieved.[9] 
      
Fig. 4 SEM of spray dried F1 without (left) and with (right) phage CP20. The same scale bar 
applies to both images. 
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3.5 Storage and Transport 
The supplemented phase diagram in Figure 3 suggests that the developed powder will have 
long-term physical stability without the need for refrigeration when a low relative humidity 
is maintained in the packaging. The biological stability of the phage in the powder during 
storage and transport will be determined. 
4. Conclusions 
Mechanistic models were used to select formulation and spray drying process parameters 
for stabilizing phage. Further results will be presented at the conference.  
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